About Adial Pharmaceuticals
Adial Pharmaceuticals is a company based in Charlottesville (United States) founded in 2010 by Bankole Johnson. Adial Pharmaceuticals has raised $7.7 million across 15 funding rounds from investors including Keystone Capital Partners, Coastlands Capital and Boxer Capital. The company has 7 employees as of December 31, 2024. Adial Pharmaceuticals has completed 1 acquisition, including Azora Therapeutics. Adial Pharmaceuticals offers products and services including AD04. Adial Pharmaceuticals operates in a competitive market with competitors including Indivior, Biotie, Ethypharm, Braeburn and Amygdala Neurosciences, among others.
- Headquarter Charlottesville, United States
- Employees 7 as on 31 Dec, 2024
- Founders Bankole Johnson
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adial Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$13.2 M (USD)-70.33as on Dec 31, 2024
-
EBITDA
-$8.28 M (USD)-20.28as on Dec 31, 2024
-
Total Equity Funding
$7.7 M (USD)
in 15 rounds
-
Latest Funding Round
$64 M (USD), Post-IPO
Jun 11, 2026
-
Investors
Keystone Capital Partners
& 3 more
-
Employee Count
7
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adial Pharmaceuticals
Adial Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ADIL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Adial Pharmaceuticals
Adial Pharmaceuticals offers a comprehensive portfolio of products and services, including AD04.
Genetically targeted treatment for alcohol use disorder via serotonin receptor antagonism
Funding Insights of Adial Pharmaceuticals
Adial Pharmaceuticals has successfully raised a total of $7.7M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $64 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adial Pharmaceuticals
Adial Pharmaceuticals has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Keystone Capital Partners, Coastlands Capital and Boxer Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment firm based in New York is operated.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Adial Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adial Pharmaceuticals
Adial Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Azora Therapeutics.
Investment portfolio details for Adial Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapies for autoinflammatory diseases are developed.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Adial Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Adial Pharmaceuticals
Detailed financials for Adial Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adial Pharmaceuticals Comparisons
Peer comparison for Adial Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adial Pharmaceuticals
Adial Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Biotie, Ethypharm, Braeburn and Amygdala Neurosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for opioid addiction treatment are developed and commercialized.
|
|
| Locked | Locked | Locked |
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Long-acting therapies for opioid addiction and chronic pain are developed.
|
|
| Locked | Locked | Locked |
Therapies for substance use disorders are developed by Amygdala Neurosciences.
|
|
| Locked | Locked | Locked |
French Biotech startup that develops to clinical trial stage the molecules it has in-licensed
|
Detailed competitors of Adial Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adial Pharmaceuticals
Complete news archive for Adial Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adial Pharmaceuticals
Adial Pharmaceuticals was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Adial Pharmaceuticals is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Adial Pharmaceuticals is a funded company, having raised a total of $7.7M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Adial Pharmaceuticals is 7.
Adial Pharmaceuticals was founded in 2010 and is headquartered in Charlottesville, United States. Therapeutics for addiction disorders are developed, with a focus on genetically targeted drugs such as AD04 for alcohol use disorder. Adenosine analogues under the Purnovate platform are also pursued for inflammatory and neurotransmission-related conditions. Operations center on pharmaceutical research and development in the biotech sector.
Adial Pharmaceuticals's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
Adial Pharmaceuticals offers AD04.
Yes, Adial Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ADIL.
Adial Pharmaceuticals has made 1 acquisition, including Azora Therapeutics.
Adial Pharmaceuticals has 4 investors. Key investors include Keystone Capital Partners, Coastlands Capital, Boxer Capital, and Stonepine.
The ticker symbol of Adial Pharmaceuticals is ADIL on NASDAQ.